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Abstract Although long-term exposure of the brain to
increased GH/IGF-1 likely inﬂuences cerebral functions,
no in vivo studies have been directed towards changes of
the brain structure in acromegaly. Here, we used high
resolution magnetic resonance images to compare volumes
of gray matter (GM), white matter (WM) and cerebrospinal
ﬂuid (CSF) of forty-four patients with acromegaly to an
age and gender matched, healthy control group (n = 44).
In addition, white matter lesions (WMLs) were quantiﬁed
and graded. Patients exhibited larger GM (?3.7% com-
pared with controls, P = 0.018) and WM volumes
(?5.1%, P = 0.035) at the expense of CSF. Differences of
WML counts between patients and controls were subtle,
however, showing more patients in the 21–40 lesions
category (P = 0.044). In conclusion, this MRI study pro-
vides ﬁrst evidence that acromegalic patients exhibit
disturbances of the macroscopic brain tissue architecture.
Furthermore, acromegalic patients may have an increased
risk of neurovascular pathology, likely due to secondary
metabolic and vascular comorbidities.
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Introduction
Acromegaly is characterized by excessive levels of growth
hormone (GH) and insulin-like-growth factor 1 (IGF-1)
that are caused by pituitary adenomas in most cases. The
clinical condition is associated with a vast range of com-
plications and comorbidities such as organomegaly,
skeletal deformations with secondary arthropathy, diabetes
mellitus, arterial hypertension, secondary pituitary deﬁ-
ciency, and neurological complications such as nerve
compression syndromes [1]. With regard to psychiatric
syndromes, both personality changes and a psychopatho-
logical risk proﬁle with an increased prevalence of
affective disorders have been suspected [2–7].
The increasing attention for neuropsychiatric aspects of
acromegaly is concurring with preclinical research that has
gained insight into the role of GH and IGF-1 in brain func-
tion. Both factors are involved in the development of the
brain [8–10]. More speciﬁcally, GH and IGF-1 play a part in
the regulation of brain growth including neuronal cell pro-
liferation, differentiation and myelination during develop-
ment [11–13]. Further, both postnatally and in the adult
rodent, IGF-1 promotes neurogenesis and synaptogenesis in
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disruption of IGF-1 gene function results in reduced brain
size,CNShypomyelinationandlossofhippocampalgranule
and striatal parvalbumin-containing neurons [15].
While many of the effects of IGF-1 and GH in the brain
are mediated by locally produced hormones, also circu-
lating hormones can reach the brain after crossing or
bypassing the blood brain barrier [16]. In acromegaly, from
6 to 10 years of hormone excess passes until clinical signs
or symptoms of acromegaly lead to the diagnostic work-up
and treatment [17]. Such long-lasting exposure to IGF-1
and GH interferes with regulation of trophic processes in
many organ systems [1], and may be supposed to affect
brain function and structure. Here, magnetic resonance
imaging (MRI) provides a number of techniques that allow
a non-invasive characterization of neuropathological
changes, yet no quantitative analyses of brain changes in
acromegaly have been presented so far.
We investigated if the GH and IGF-1 excess in acro-
megalic patients alters the macroscopic structure of the
brain as determined by MRI. More speciﬁcally, we gained
volumes of the main compartments of the brain—gray
matter (GM), white matter (WM), and cerebrospinal ﬂuid
(CSF)—from high resolution MRI. The GM compartment
includes the whole cortex and the deep nuclei, whereas the
WM compartment represents the entirety of the ﬁber tracts.
In addition, we explored if acromegalic patients show MRI
signs of neurovascular pathology that may add to their
neuropsychiatric comorbidity.
Methods
Subject recruitment and clinical characterization
Between 04/2006 and 07/2007, 44 patients with previously
diagnosed acromegaly were recruited from the endocrine
outpatient unit of the Max Planck Institute of Psychiatry
(MPIP), Munich, and the Department of Internal Medicine,
Ludwig-Maximilians-Universita ¨t, Munich. All patients
gave their written informed consent to participate in the
study. Patients received a comprehensive medical inter-
view with regard to initial symptomatology, disease
development, tumor characteristics, previous and current
disease speciﬁc therapy, and current complaints. After
exploration of their past medical history and systematic
inquiry on comorbidities such as cardiovascular diseases,
metabolic features, respiratory features, bone and joint
features, malignancies, and secondary endocrine compli-
cations, patients were examined.
Additionally, basal hormonal levels and metabolic
parameters were obtained in a fasting state at the day of
study participation (between 8.00 and 10.00 am). Coronary
artery disease, type 2 diabetes and dyslipidemia were
recorded from physician’s diagnoses, intake of respective
medications, or abnormal laboratory values from patient’s
records. In the case of missing data or uncertainty, addi-
tional information was obtained by ﬁle review. Diagnoses
of somatic comorbidities were made according to the
respective guidelines. Serum concentrations of GH were
measured using the automated Advantage chemilumines-
cent assay system (Nichols Diagnostics Institute, Bad
Vilbel, Germany). IGF-1 was measured by automated
chemiluminescent assays (IMMULITE 2000). Biochemical
control was deﬁned by (a) GH below 1 lg/l during a glu-
cose tolerance test over 2 h, and (b) IGF-1 level within two
standard deviations of an age- and gender-adjusted nor-
mative sample [18]. IGF-1 values are indicated as a
multiple of the upper limit of normal (xULN), calculated as
follows: xULNIGF-1 = IGF-1 value/95th percentile of the
age and gender adjusted normal range.
We further introduced a parameter ‘‘time of hormonal
excess’’ aimed to inform on the time the patient has been
exposed to increased IGF-1 or GH. It was calculated from
the time of diagnosis until the date of MRI, augmented by
an estimated 8 years of subclinically increased hormone
levels as reported [17], and corrected for the time since
documented biochemical control.
Forty-four age and gender matched controls were
selected case-by-case from a database of 200 neuropsy-
chiatrically healthy control subjects that were recruited and
characterized at the MPIP. Medical comorbidities such as
arterial hypertension, dyslipidemia and diabetes, as well as
alcohol abuse and nicotine abuse were explored by ques-
tionnaires and standard laboratory tests.
Magnetic resonance image acquisition
TheMRIprotocolcomprisedaxialﬂuidattenuatedinversion
recovery (FLAIR) images (TR 10,002 ms, TE 122.8 ms,
FOV 24 9 24 cm
2, in-plane resolution 0.9375 9
1.071 mm
2, 20 slices, slice thickness 5 mm), axial proton
density and T2-weighted double echo sequence (spin echo,
TR 6,540 ms, TE 20.7/113.8 ms, FOV 24 9 24 cm
2, in-
plane resolution 0.5357 9 0.5357 mm
2, 20 slices, slice
thickness 3 mm), and sagittal T1 weighted high resolution
image (spin echo, TR 9.7 ms, TE 2.1 ms, FOV
25 9 25 cm
2, in-plane resolution 0.875 9 0.875 mm
2,
124–132 slices, slice thickness 1.2 mm; Fig. 1a).
Radiological assessment of white matter integrity
Rating of white matter lesions (WML) was performed on
axial FLAIR images by two raters experienced in neuro-
radiological ﬁlm reading (Fig. 1b). Both readers were blind
for the main diagnosis, age and comorbidities of the subject
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training session. All axial FLAIR slices of a subject were
screened simultaneously on a digital 5 9 5 panel, and focal
WM hyperintensities larger than 2 mm were counted.
Hyperintense bands adjacent to the anterior tip and pos-
terior parts of the lateral ventricles as often present as
normal variant, were disregarded. Lesions with continuous
extension over two or more slices were counted as one
lesion. After independent runs of each raters, all cases with
discrepant lesion counts were re-assessed by both raters
until consensus was achieved. In ambiguous cases of focal
hyperintensities, proton density and axial T2 weighted
images were consulted in addition. Due to the skewed
distribution of WML counts and the increasing degree of
uncertainty with higher counts, subjects were classiﬁed into
WML categories as follows: class 0: no WML; class I: 1–5
lesions; class II: 6–10 lesions; class III: 11–20 lesions;
class IV: 21–40 lesions; class V: more than 40 lesions.
Brain tissue volumetry
High resolution T1-weighted images were segmentated
into GM, WM, and CSF using the Matlab based (Matlab
7.0.4, MathWorks, Natick, USA) statistical parametric
mapping (http://www.ﬁl.ion.ucl.ac. uk/spm, version SPM5)
software package. The implemented algorithm uses the
uniﬁed segmentation approach [19] to provide voxelwise
maps of GM, WM, and CSF in normalized space. For
segmentation, prior probability maps (resolution
2 9 2 9 2m m
3, standard SPM5 distribution) as based on
the International Consortium for Brain Mapping maps
([ICBM], http://www.loni.ucla.edu/ ICBM), along with
default processing parameters were employed. The volume
for each tissue class (GMtotal,W M total, CSFtotal) was cal-
culated as total of voxel intensities of normalized and
modulated volume maps after masking out non-brain and
non-CSF voxels. This approach has recently been validated
and proven to be robust towards inﬂuences from patho-
logical WM changes [20]. For this, a mask from a large
sample (N[500) of equally processed images that mat-
ched the intracranial vault was used (Fig. 1c–e). The
masking procedure particularly improves measurement
accuracy of the CSF volume and consequently of the total
intracranial volume (TIV, calculated as GMtotal ? WMto-
tal ? CSFtotal). In addition, volumes normalized to TIV
were calculated (GMnorm,W M norm, CSFnorm).
Fig. 1 Examples of raw
images and segmentation into
GM, WM and CSF. a Example
of high resolution T1-weighted
image in sagittal view. b
Typical multifocal white matter
lesions, apparent as
hyperintense areas on a FLAIR
image of a study patient. c–e
Exemplary axial slice of GM,
WM and CSF of a patient after
segmentation and spatial
normalization. All maps were
corrected for erronous inclusion
of non-brain and non-CSF areas
by applying a mask as overlaid
in (e)
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Comparison of comorbidities and WML
The frequency of comorbid diagnoses and anthropometric
measures were compared using Fisher’s exact tests or t-
tests, respectively. The percentage of subjects in each
WML class was compared between the patient and control
group using two-sided Pearson chi square tests. The anal-
ysis was repeated separately for patients with shorter and
longer exposure to hormone excess.
Analysis of volumes of gray matter, white matter,
cerebrospinal ﬂuid, and total intracranial volume
GMtotal,W M total, CSFtotal, and TIV were compared
between patients and controls using analysis of covariance
(ANCOVA) with age and gender as covariates. As a large
proportion of the variance of the brain’s volume is deter-
mined the TIV, the analyses were repeated with GMnorm,
WMnorm, and CSFnorm.
Relation of volumetric measures to estimated disease
duration and current hormonal status
Todetectarelationshipbetweenthetimeofhormonalexcess
and volumetric changes, patients were stratiﬁed into sub-
groups according to a median (10.9 years) split. ANCOVA
was performed using a three-level group factor (controls,
patients with below median [subgroup I] and above median
[subgroupII]timeofhormonalexcess)andageandgenderas
covariates. Dependent variables were absolute brain volume
(GMtotal ? WMtotal), GMtotal,W M total, CSFtotal, the respec-
tive normalized volumes, and TIV. Subgroups did not differ
with regard to gender distribution (women/men 13/9 and
10/12, P = 0.547, Fisher’s exact test) and mean age
(56.5 ± 14.0 years and 52.2 ± 13.8 years, P = 0.305,
t-test). Expectedly, the mean age at diagnosis was lower
in subgroup II (51.4 ± 14.4 and 42.5 ± 13.1 years,
P = 0.037, t-test). Covariation of absolute and normalized
volumes of the whole brain, GM, WM and CSF, and TIV
with the current hormonal status was investigated by (a)
multiple regression of the volumetric parameters on age,
gender and xULNIGF-1, and (b) by comparing patients with
(N = 27) and without (N = 17) biochemical control at the
time of MRI, covarying for age and gender. The statistical
signiﬁcance threshold was set to 0.05.
Relation of brain measures with vascular comorbidity
status
After obtaining the main ﬁnding of an association between
acromegaly and brain volume, cardiovascular comorbidities
found to be different in frequency between patients and
controls (arterial hypertension and diabetes, see result sec-
tion) were summarized to one factor, and two-factoral
ANCOVA was performed to investigate if this comorbidity
status or its interaction with acromegaly underlies these
effects. Age and gender were used as covariates.
Results
Demographic and clinical characteristics
In brief, the average time between the diagnosis of acro-
megaly and MRI was 7.8 ± 6.8 years. The estimated time
of hormone excess was 12.5 ± 5.2 years. Patients showed a
higher frequency of arterial hypertension (P = 0.001) and
diabetes (P = 0.002, Fisher’s exact tests) and larger waist
circumference(P\0.001)andBMIvalues(P\0.001,two
sample t-tests) compared with controls (Table 1).
Patient/control comparison of volumetric measures
Patients exhibited about 3.7% larger absolute GM volumes
than controls (627 ± 78 ml vs. 605 ± 84 ml, F1,40 =
5.854, P = 0.018) and about 5.1% larger absolute WM
volumes than controls (460 ± 63 ml vs. 438 ± 63 ml,
F1,40 = 4.607, P = 0.035). Absolute CSF volume was
decreased in patients by about 3.7% (407 ± 76 ml vs.
423 ± 77 ml), and TIV was increased in patients by about
2% (1,494 ± 156 ml vs. 1,465 ± 153 ml), yet, these dif-
ferences were not signiﬁcant (P = 0.185 and P = 0.174,
respectively) (Fig. 2). A similar pattern were revealed for
normalized volumes with the CSFnorm difference reaching
signiﬁcance (GMnorm: F1,40 = 3.619, P = 0.061, WMnorm:
F1,40 = 4.066, P = 0.046, CSFnorm: F1,40 = 6.365,
P = 0.014).Insummary,thispatternforwardedincreasesof
the GM and WM compartment with a volume gain of each
compartment of about 22 ml at the expense of the CSF
spaces and accompanied by (non-signiﬁcant) TIV increases.
Inﬂuence of the estimated time of hormonal excess
Analysis of absolute brain volumes between controls and
patients with shorter (subgroup I) and longer (subgroup II)
exposure to increased hormone levels revealed a signiﬁcant
main effect (F2,39 = 3.450, P = 0.036). Post-hoc tests
pointed to a difference between controls and subgroup I
(P = 0.014, Fig. 3). Subgroup II was interpositioned
between the control group and subgroup I with non-sig-
niﬁcant differences to either group. A similar pattern
emerged for GM (F2,39 = 3.117, P = 0.050; post-hoc
comparison of control group vs. subgroup I: P = 0.022)
and WM (F2,39 = 2.751, P = 0.070; post-hoc comparison
180 Pituitary (2009) 12:177–185
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TIV the main effect remained non-signiﬁcant (P = 0.111
and P = 0.412, respectively). Analysis of the normalized
volumes revealed similar patterns for GMnorm and
WMnorm, while the main effect for the comparison of
CSFnorm was signiﬁcant (F2,39 = 4.864, P = 0.010), with
post-hoc comparisons showing decreased CSFnorm com-
paring subgroup I with controls (P = 0.002), and a trend
difference between subgroup I and II (P = 0.077).
Correlation with current hormonal status
No signiﬁcant differences of GMtotal,W M total,B V total,
CSFtotal or TIV were found between biochemically con-
trolled and non-controlled patients. In addition, multiple
regression analysis of GM, WM and BV showed no sig-
niﬁcant contribution of xULNIGF-1.
White matter lesion analysis
An equal proportion of patients and controls (34.1%) was
classiﬁed into the lowest WML class (no lesions). A higher
proportion of patients was found in WML class IV (21–40
lesions, 18.2% vs. 4.6%, P = 0.044, Pearson chi square
test) (Fig. 4). This difference was also seen in a compari-
son of the controls with the subgroup of patients with
longer exposure to hormone excess (P = 0.024), however
not in the subgroup with shorter exposure (P = 0.188). No
differences were seen with regard to the other WML
categories.
Table 1 Demographic and
clinical characteristics of
patients and controls
a Student’s t-test, two-sided
b Fisher’s exact test, two-sided
Patients (N = 44) Controls (N = 44) P-value
Age, years 54.1 (13.7) 53.8 (13.4) 0.828
a
Gender distribution 52% females 52% females 1.000
b
Age at diagnosis, years 46.9 (14.4) N/A N/A
Years since biochemical control 3.2 (5.5) N/A N/A
Estimated time of hormonal excess, years 12.5 (5.2) N/A N/A
Biochemically controlled at study entry 27 (61%) N/A N/A
Type of adenoma
Macroadenoma 36 (82%) N/A N/A
Microademona 4 (9%) N/A N/A
Not known 4 (9%) N/A N/A
Therapy
Neurosurgery 41 (93%) N/A N/A
Radiation 6 (14%) N/A N/A
Medical therapy 27 (61%) N/A N/A
Arrhythmia 10 (23%) N/A N/A
Cardiomyopathy 5 (11%) N/A N/A
Cerebrovascular diseases 4 (9%) N/A N/A
Hypertension 27 (61%) 11 (25%) 0.001
b
Coronary artery disease 5 (11%) N/A N/A
Myocardial infarction 1 (2%) N/A N/A
Arthralgia 28 (64%) N/A N/A
Diabetes mellitus 14 (32%) 2 (5%) 0.002
b
Pituitary deﬁciency 23 (52%) N/A N/A
Sleep apnea 16 (36%) N/A N/A
Disturbances of lipid metabolism 19 (43%) 13 (30%) 0.186
b
Alcohol abuse 10 (23%) 5 (11%) 0.166
b
Nicotine abuse 24 (55%) 20 (45%) 0.394
b
Anthropometric measures
Height, cm 173.1 (11.7) 170.3 (9.2) 0.199
a
Waist circumference, cm 98.1 (12.7) 87.4 (11.1) \0.001
a
Body Mass Index (BMI), kg/m
2 29.0 (5.2) 24.8 (2.7) \0.001
a
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comorbidity status
The combined arterial hypertension/diabetes status variable
was found to be associated with lower GM volume in
patients and controls at trend level (P = 0.092), not
interacting with the main diagnosis (P = 0.480). For WM
and brain, only the main diagnosis (WM: P = 0.031; brain:
P = 0.007) but not the comorbidity status contributed
signiﬁcantly (WM: P = 0.533; brain: P = 0.217).
Discussion
Due to the widespread functions of IGF-1 and GH in many
organ systems, acromegaly is a complex systemic disease.
Similarly to other organ systems, the central nervous sys-
tem may be affected by long-term exposure to increased
levels of GH and IGF-1, however, no in vivo studies on
brain structure (or metabolism) in acromegaly have been
reported to our knowledge. In brief, the data from this
study demonstrates that: (1) the excess of GH and IGF-1 is
associated with a volumetric expansion of the GM (?3.7%)
and WM compartment (?5.1%) of the brain, accompanied
by compensatory CSF volume decreases and total intra-
cranial volume increases, (2) these changes seem to occur
during the ﬁrst 10 years of hormone excess, and (3)
patients exhibit more focal hyperintense WM lesions that
served as marker of neurovascular pathology.
The volumetric expansion of GM and WM may be the
result of the long-lasting exposure of neuronal or glial cells
towards systemically elevated GH and IGF-1. Both factors
are known to mediate the maturation of these cell types
during brain development and continue to have pleiotropic
effects in adulthood [10, 21]. IGF-1 overexpression—
though not directly comparable to systemically elevated
IGF-1/GH levels—has been reported to lead to markedly
increased brain size in mice [22], whereas IGF-1 knockout
mice showed smaller brains [15]. These reports suggest
that IGF-1 mediated trophic effects on the brain may
indeed reach a macroscopic scale. It is not known, how-
ever, to what degree the altered brain phenotypes translated
into behavioral changes or more generally, functional
deﬁcits, since data on these characteristics were not sys-
temically evaluated [15, 21, 22]. Central application of
IGF-1 in adult rodents resulted in decreased depression-like
behavior, however, no volumetric information was pro-
vided in this speciﬁc study [23].
With regard to WM, both increases of the axonal vol-
ume (physiologically about 46% of WM) and of myelin
sheaths (i.e., oligodendrocytes, physiologically about 24%
of WM) are conceivable [24]. In view of reports on
swelling of myelin sheaths in consequence to increased
Fig. 2 Absolute volumes of gray matter, white matter and cerebro-
spinal ﬂuid in acromegalic patients (N = 44) and control subjects
(N = 44). Bars show estimated marginal means (?SEM) corrected
for age and gender, of the three compartments for patients and
controls. GM: gray matter, WM: white matter, CSF: cerebrospinal
ﬂuid. *Signiﬁcant differences for the group factor emerged for
comparison of GM (P = 0.018) and WM (P = 0.035). CSF differ-
ences were signiﬁcant for normalized, but not for absolute volumes
(see result section)
Fig. 3 Inﬂuence of the estimated time of hormone excess. Depiction
of estimated marginal means (?SEM) after correction for age and
gender effects, relative to mean values of the control group. Post-hoc
comparisons revealed signiﬁcant increases (*P\0.05) in the patient
subgroup I (below median 10.9 years of estimated hormone exposure)
with regard to GMtotal,W M total and absolute total brain volume. See
result section for the analysis of normalized volumes
Fig. 4 White matter lesion counts. Relative frequencies of patients
and controls in the six WML categories are given. Patients were
signiﬁcantly overrepresented in the 21–40 WML class (P = 0.044,
Pearson chi square test)
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1-overexpressing mice, expansion of the myelin compart-
ment may explain our observation [22]. Advanced MRI
including diffusion tensor imaging and
1H-MR-spectros-
copy may be used to assign the volume changes more
speciﬁcally to a histopathological substrate. With regard to
GM, the observed changes may reﬂect expansion of axons
and dendrites of fully differentiated neurons. Experimental
histopathological work and theoretical considerations,
however, suggest that the glia cell compartment may be an
equally important source of macroscopical volume changes
[25]. Neurogenesis triggered by IGF-1 and GH, i.e., an
increased number of neurons, seems more unlikely as
neurogenesis is restricted to few brain regions such as the
hippocampus.
In general, decreases of local or global GM or WM
volume due to primary neurodegeneration or secondary to
inﬂammatory conditions, neurovascular pathology or toxic
agents are found more often than volume increases [26].
We investigated the inﬂuence of arterial hypertension and
diabetes, the two cardiovascular factors signiﬁcantly more
frequent in the acromegaly group in this sample, ﬁnding
trend decreases of GMtotal volumes across in association
with the presence of these comorbidities across both
groups, and no effects (P[0.10) for WMtotal and BVtotal.
This strengthens that volume effects are unlikely to be
driven by cardiovascular comorbidity but are rather spe-
ciﬁc to acromegaly. Disease speciﬁc increases of GM
volume are rather exceptional and mostly represented in
the spectrum of neurodevelopmental disorders such as
hemimegalencephaly or cerebral gigantism. Patients with
these disorders often present with general developmental
delay or seizures. Also cortical dysplasia may be volu-
metrically expansive, however is highly focal in most cases
[27]. Increases of basal ganglia volumes have been
observed as consequence of long-standing neuroleptic drug
treatment [28].
The split into patient subgroups with shorter and longer
hormone excess allowed to generate a number of new
hypotheses: ﬁrst, no linear relationship between the esti-
mated time of hormone excess and brain size could be
observed. Rather, for both GM and WM, the volume
increases seem to saturate after about 10 years. Even a
slight decrease was seen after 10 years that, however,
failed to reach signiﬁcance. Second, as far as extractable
from cross-sectional data, CSF spaces were decreased ﬁrst,
while TIV continued to increase, giving space to CSF that
returned to normal absolute values. This pattern may
indicate that the brain volume increase preceeds (or over-
rides) changes of the intracranial vault in the early phase.
As some IGF-1/GH effects in acromegaly, for instance on
bones, skull and joints, are reversible only at initial stages,
but not if the disease is left untreated for several years [1],
it remains pivotal to determine if there is also a critical
limit up to which cerebral changes are reversible. We also
revealed no correlation between the current hormone status
and brain volumes, conﬁrming that brain volume changes
are long-term effects and unlikely to follow short term
ﬂuctuations of IGF-1 (or GH).
Although widespread anatomical systems may be
affected by the ubiquitary presence of IGF-1 and GH in the
brain, some regions may be more susceptible than others
[29]. Clinically, however, a large variety of neuropsychi-
atric symptoms rather argues for disturbances of multiple
circuits, including the regulation of affect and anxiety
related behavior, pain perception and higher cognitive
functions. It should be mentioned that we do not know yet
to which degree the observed structural changes actually
affect brain function. Future studies in acromegalic patients
are underway to determine if psychopathological or cog-
nitive abnormalities are indeed associated with these
morphological changes.
Differences of WML counts were subtle with patients
being overrepresented in only one of the higher WML
lesion categories. The effect of acromegaly on this simple
neurovascular parenchymal marker was into the expected
direction, as acromegaly provokes cardiovascular and
metabolic complications including arterial hypertension
and diabetes. Both diagnoses were indeed more frequent in
patients than controls and are known to be associated with
increased number of WML [30, 31]. Therefore, the WML
ﬁnding of this study probably reﬂects the increased car-
diovascular and metabolic comorbidity. In addition, the
WML effect was stronger in the subgroup with longer
hormone excess, which further concurs with the hypothesis
that hypertension and cardiovascular diseases develop as a
consequence of chronic alterations of the endothelial and
cardiac function in acromegaly [1]. We cannot exclude,
however, that IGF-1/GH increase the susceptibility to
ischemia by different mechanismus, e.g., by reducing the
remyelination potential. In any case, structural damage to
the ﬁber tracts by microangiopathy can add to cognitive
decline [32] and makes careful monitoring and treatment of
cardiovascular and metabolic comorbidities mandatory.
The study is mainly limited by its cross-sectional design
and heterogeneous patient sample with different disease
duration.Inaddition,themethodofstratiﬁcationintoshorter
and longer duration of hormone excess is debatable. We
performed a supportive analysis using linear regression to
explore if the estimated time of hormone excess allows
correlates with total brain size, yet found no improvementin
themodelﬁtcomparedwiththegroupstratiﬁcation(datanot
shown).Further, asthevariableisacompoundofthreeother
variables (time of diagnosis, estimated 8 years of previous
hormone excess and time since biochemical control), its
reliability is generally limited. Methodologically, TIV is a
Pituitary (2009) 12:177–185 183
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ever, in the case of acromegaly it may not be stable. Despite
this, we also analyzed volumetric measures normalized to
TIV,asTIVexplainsalargeproportionofthevarianceofthe
brain volume. Subtle changes of the group statistics con-
ﬁrmed that TIV covaried with the disease process which
underlines the importance to match for other factors co-
correlating with TIV, particularly gender and body height.
Furthermore, the calculation of total CSF volume including
the external subarachnoid spaces is challenging for auto-
mated methods that do not explicitly model extradural
tissue. This may in part explain the larger group overlap for
analysis of CSF and TIV.
In conclusion, we provide ﬁrst in vivo evidence of a
disturbed macroscopic brain architecture in acromegaly
with increases of total GD and WM volumes. These
changes seem to occur during the ﬁrst 10 years of hormone
excess at the expense of the CSF compartment, with par-
allel increases of the total intracranial volume. In addition,
a tendency for increased neurovascular pathology is dem-
onstrated, most likely due more frequent metabolic and
cardiovascular comorbidities. Future work will need to
clarify which brain functions and neuropsychiatric syn-
dromes relate to these changes, and if treatment can reverse
them.
Acknowledgments We thank Iris Miedl, Doris Goy-Alsing, Rosa
Hemauer, Reinhold Borschke and Elke Schreiter for MRI data
acquisition and excellent patient care.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic
complications of acromegaly: epidemiology, pathogenesis, and
management. Endocr Rev 25:102–152. doi:10.1210/er.2002-0022
2. Bonapart IE, van Domburg R, ten Have SM, de Herder WW,
Erdman RA, Janssen JA et al (2005) The ‘bio-assay’ quality of
life might be a better marker of disease activity in acromegalic
patients than serum total IGF-I concentrations. Eur J Endocrinol
152:217–224. doi:10.1530/eje.1.01838
3. Blickenstorfer E (1953) Psychiatric and genealogic study of 51
cases of acromegaly. Schweiz Arch Neurol Psychiatr 71:371–374
4. Blickenstorfer E (1953) Genealogy and psychopathology of 51
acromegaly patients. Acta Endocrinol (Copenh) 13:123–137
5. Blickenstorfer E (1951) Psychiatry and genealogy of acromegaly;
studies from the conﬁnes of psychopathology of endocrinology.
Arch Psychiatr Nervenkr Z Gesamte. Neurol Psychiatr (Bucur)
186:88–122
6. Bleuler M (1951) Personality changes in pituitary disorders. BMJ
1:580–581
7. Bleuler M (1951) The psychopathology of acromegaly. J Nerv
Ment Dis 113:497–511.doi:10.1097/00005053-195101000-00050
8. Russo VC, Gluckman PD, Feldman EL, Werther GA (2005) The
insulin-like growth factor system and its pleiotropic functions in
brain. Endocr Rev 26:916–943. doi:10.1210/er.2004-0024
9. Aberg MA, Aberg ND, Palmer TD, Alborn AM, Carlsson-
Skwirut C, Bang P et al (2003) IGF-I has a direct proliferative
effect in adult hippocampal progenitor cells. Mol Cell Neurosci
24:23–40. doi:10.1016/S1044-7431(03)00082-4
10. Schneider HJ, Pagotto U, Stalla GK (2003) Central effects of the
somatotropic system. Eur J Endocrinol 149:377–392. doi:
10.1530/eje.0.1490377
11. Ransome MI, Goldshmit Y, Bartlett PF, Waters MJ, Turnley AM
(2004) Comparative analysis of CNS populations in knockout
mice with altered growth hormone responsiveness. Eur J Neu-
rosci 19:2069–2079. doi:10.1111/j.0953-816X.2004.03308.x
12. Ajo R, Cacicedo L, Navarro C, Sanchez-Franco F (2003) Growth
hormone action on proliferation and differentiation of cerebral
cortical cells from fetal rat. Endocrinology 144:1086–1097. doi:
10.1210/en.2002-220667
13. O’Kusky JR, Ye P, D’Ercole AJ (2000) Insulin-like growth
factor-I promotes neurogenesis and synaptogenesis in the hip-
pocampal dentate gyrus during postnatal development. J Neurosci
20:8435–8442
14. Aberg MA, Aberg ND, Hedbacker H, Oscarsson J, Eriksson PS
(2000) Peripheral infusion of IGF-I selectively induces neuro-
genesis in the adult rat hippocampus. J Neurosci 20:2896–2903
15. Beck KD, Powell-Braxton L, Widmer HR, Valverde J, Hefti F
(1995) Igf1 gene disruption results in reduced brain size, CNS
hypomyelination, and loss of hippocampal granule and striatal
parvalbumin-containing neurons. Neuron 14:717–730. doi:
10.1016/0896-6273(95)90216-3
16. Coculescu M (1999) Blood-brain barrier for human growth hor-
mone and insulin-like growth factor-I. J Pediatr Endocrinol
Metab 12:113–124
17. van der Lely AJ, Beckers A, Daly AF, Lamberts SWJ, Clemmons
DR (2005) Acromegaly: pathology, diagnosis and treatment.
Taylor & Francis, Boca Raton
18. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L,
Ho K et al (2000) Criteria for cure of acromegaly: a consensus
statement. J Clin Endocrinol Metab 85:526–529. doi:10.1210/jc.
85.2.526
19. Ashburner J, Friston KJ (2005) Uniﬁed segmentation. Neuroim-
age 26:839–851. doi:10.1016/j.neuroimage.2005.02.018
20. O’Sullivan M, Measurement of brain atrophy in subcortical va-
sculr disease: A comparison of different approaches and the
impact of ischaemic lesions. NeuroImage (in press)
21. D’Ercole AJ, Ye P, O’Kusky JR (2002) Mutant mouse models of
insulin-like growth factor actions in the central nervous system.
Neuropeptides 36:209–220. doi:10.1054/npep.2002.0893
22. Carson MJ, Behringer RR, Brinster RL, McMorris FA (1993)
Insulin-like growth factor I increases brain growth and central
nervous system myelination in transgenic mice. Neuron 10:729–
740. doi:10.1016/0896-6273(93)90173-O
23. Hoshaw BA, Malberg JE, Lucki I (2005) Central administration
of IGF-I and BDNF leads to long-lasting antidepressant-like
effects. Brain Res 1037:204–208. doi:10.1016/j.brainres.2005.01.
007
24. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ (2002)
Measurement of atrophy in multiple sclerosis: pathological basis,
methodological aspects and clinical relevance. Brain 125:1676–
1695. doi:10.1093/brain/awf177
25. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD,
Meltzer HY et al (1999) Morphometric evidence for neuronal and
glial prefrontal cell pathology in major depression. Biol Psychi-
atry 45:1085–1098. doi:10.1016/S0006-3223(99)00041-4
26. Giannakopoulos P, Hof PR, Michel JP, Guimon J, Bouras C
(1997) Cerebral cortex pathology in aging and Alzheimer’s
184 Pituitary (2009) 12:177–185
123disease: a quantitative survey of large hospital-based geriatric and
psychiatric cohorts. Brain Res Brain Res Rev 25:217–245. doi:
10.1016/S0165-0173(97)00023-4
27. Mathern GW, Andres M, Salamon N, Chandra PS, Andre VM,
Cepeda C et al (2007) A hypothesis regarding the pathogenesis
and epileptogenesis of pediatric cortical dysplasia and hemim-
egalencephaly based on MRI cerebral volumes and NeuN cortical
cell densities. Epilepsia 48(Suppl 5):74–78. doi:10.1111/j.
1528-1167.2007.01292.x
28. Corson PW, Nopoulos P, Miller DD, Arndt S, Andreasen NC
(1999) Change in basal ganglia volume over 2 years in patients
with schizophrenia: typical versus atypical neuroleptics. Am J
Psychiatry 156:1200–1204
29. Aberg ND, Brywe KG, Isgaard J (2006) Aspects of growth hor-
mone and insulin-like growth factor-I related to neuroprotection,
regeneration, and functional plasticity in the adult brain. Scien-
tiﬁcWorldJournal 6:53–80. doi:10.1100/tsw.2006.22
30. Jongen C, van der Grond J, Kappelle LJ, Biessels GJ, Viergever
MA, Pluim JP (2007) Automated measurement of brain and white
matter lesion volume in type 2 diabetes mellitus. Diabetologia
50:1509–1516. doi:10.1007/s00125-007-0688-y
31. de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman
A, van Gijn J et al (2002) Hypertension and cerebral white matter
lesions in a prospective cohort study. Brain 125:765–772. doi:
10.1093/brain/awf077
32. Smith EE, Gurol ME, Eng JA, Engel CR, Nguyen TN, Rosand J
et al (2004) White matter lesions, cognition, and recurrent hem-
orrhage in lobar intracerebral hemorrhage. Neurology 63:1606–
1612
Pituitary (2009) 12:177–185 185
123